Related Experiment Video
Updated: Jul 19, 2026
09:10
Ex Vivo Imaging of Postnatal Cerebellar Granule Cell Migration Using Confocal Macroscopy
Published on: May 12, 2015
Summary
Plasmin inactivates C[unk] inhibitor by altering its function and immunoelectrophoretic properties. This interaction requires plasmin's active site and suggests links between fibrinolytic, kallikrein, and complement systems.
Area of Science:
- Biochemistry
- Immunology
- Proteolysis
Background:
- C[unk] inactivator inhibits multiple proteases, including plasmin.
- The interaction between plasmin and C[unk] inactivator is not fully understood.
- Potential links between fibrinolytic, kallikrein, and complement systems exist.
Purpose of the Study:
- To investigate the mechanism of plasmin-induced inactivation of C[unk] inactivator.
- To determine if plasmin's active site is required for this inactivation.
- To explore the implications for inter-system relationships in human diseases.
Main Methods:
- Incubation of plasmin with C[unk] inactivator.
- Assays for inhibitory activity.
- Use of plasmin inhibitors (soybean trypsin inhibitor, tosyl arginine methyl ester).
- Double diffusion analysis.
- Agarose and acrylamide gel immunoelectrophoresis.
Main Results:
- Plasmin reduced C[unk] inactivator activity in a time- and concentration-dependent manner.
- Plasmin-induced inactivation was prevented by blocking plasmin's active site.
- Immunological analysis showed functional and immunoelectrophoretic alterations in C[unk] inactivator.
- The active proteolytic site of plasmin is essential for this interaction.
Conclusions:
- Plasmin functionally and immunologically modifies C[unk] inactivator.
- The active site of plasmin is crucial for C[unk] inactivator inactivation.
- This interaction suggests a theoretical link between fibrinolytic, kallikrein, and complement systems with potential disease relevance.
Related Concept Videos
01:09Cytoskeletal Linker Proteins - Plakins
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.